Persistence of haloperidol in human brain tissue

American Journal of Psychiatry

Volumn 156, Issue 6, 1999, Pages 885-890

  Kornhuber, Johannes ^a   Schultz, Andreas ^b   Wiltfang, Jens ^b   Meineke, Ingolf ^b   Gleiter, Christoph H ^b   Zöchling, Robert ^b   Boissl, Karl Werner ^b   Leblhuber, Friedrich ^b   Riederer, Peter ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; KINETICS; MEDICAL DECISION MAKING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0033009682     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.6.885     Document Type: Article

References (41)

1. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M: Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54:49-55
2. Addonizio G, Susman VL, Roth SD: Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987; 22:1004-1020
3. Kornhuber J, Weller M: Neuroleptic malignant syndrome. Curr Opin Neurol 1994; 7:353-357
4. Hubbard JW, Ganes D, Midha KK: Prolonged pharmacologic activity of neuroleptic drugs. Arch Gen Psychiatry 1987; 44: 99-100
5. Ereshefsky L, Jann MW, Saklad SR, Davis CM: Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J Clin Psychiatry 1986; 47(Sept suppl):6-15
6. Cohen BM, Babb S, Campbell A, Baldessarini RJ: Persistence of haloperidol in the brain. Arch Gen Psychiatry 1988; 45:879-880
7. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb SM: Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology (Berl) 1992; 108:338-344
8. Campbell A, Baldessarini RJ: Prolonged pharmacologic activity of neuroleptics (letter). Arch Gen Psychiatry 1985; 42:637
9. Campbell A, Baldessarini RJ, Teicher MH, Kula NS: Prolonged antidopaminergic actions of single doses of butyrophenones in the rat. Psychopharmacology (Berl) 1985; 87: 161-166
10. Gsell W, Lange KW, Pfeuffer R, Heckers S, Heinsen H, Senitz D, Jellinger K, Ransmayr G, Wichart I, Vock R, Beckmann H, Riederer P: How to run a brain bank: a report from the Austro-German brain bank. J Neural Transm Suppl 1993; 39:31-70
11. Parkinson D: Sensitive analysis of butyrophenone neuroleptics by high-performance liquid chromatography with ultraviolet detection at 254 nm. J Chromatogr 1985; 341:465-472
12. Aarons L: Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991; 32:669-670
13. Beal SL, Sheiner LB: NONMEM Users Guide, Part I: Users Basic Guide: Technical Report of the Division of Clinical Pharmacology. San Francisco, University of California, 1980
14. Sheiner LB, Beal SL: Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71:1344-1348
15. Demoen PJAW: Properties and analysis of haloperidol and its dosage form. J Pharm Sci 1961; 50:350-353
16. Curry SH, Brown EA, Hu OY, Perrin JH: Liquid chromatographic assay of phenothiazine, thioxanthene and butyrophenone neuroleptics and antihistamines in blood and plasma with conventional and radial compression columns and UV and electrochemical detection. J Chromatogr 1982; 231:361-376
17. Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ: Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 1984; 11:259-269
18. Öhman R, Larsson M, Nilsson IM, Engel J, Carlsson A: Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. Naunyn Schmiedebergs Arch Pharmacol 1977; 299:105-114
19. Forsman A, Öhman R: Pharmacokinetic studies on haloperidol in man. Curr Ther Res Clin Exp 1976; 20:319-336
20. Kornhuber J, Riederer P, Reynolds GP, Beckmann H, Jellinger K, Gabriel E: 3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 1989; 75:1-10
21. Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Maziere B: In vivo assay for neuroleptic receptor binding in the striatum: positron tomography in humans. Br J Psychiatry 1987; 151:824-830
22. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B: Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl) 1989; 99:463-472
23. Farde L, Wiesel F-A, Halldin C, Sedvall G: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45:71-76
24. Harasko-van der Meer C, Brücke T, Wenger S, Fischer P, Deecke L, Podreka I: Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. J Neural Transm Gen Sect 1993; 94:217-221
25. Nyberg S, Farde L, Halldin C: Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate: preliminary findings. Arch Gen Psychiatry 1997; 54:953-958
26. Tsuneizumi T, Babb SM, Cohen BM: Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol Psychiatry 1992; 32:817-824
27. Sunderland T, Cohen BM: Blood to brain distribution of neuroleptics. Psychiatry Res 1987; 20:299-305
28. Volavka J, Cooper TB, Czobor P, Meisner M: Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 1995; 52:837-845
29. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48:739-745
30. Laduron PM, Janssen PF, Leysen JE: Spiperone: a ligand of choice for neuroleptic receptors, 2: regional distribution and in vivo displacement of neuroleptic drugs. Biochem Pharmacol 1978; 27:317-321
31. Janssen PAJ, Soudijn W, Wijngaarden I, Dresse A: Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug, III: regional distribution of pimozide and of haloperidol in the dog brain. Arzneimittelforschung 1968; 18:282-287
32. Kornhuber J, Retz W, Riederer P: Slow accumulation of psychotropic substances in the human brain: relationship to therapeutic latency of neuroleptic and antidepressant drugs? J Neural Transm Suppl 1995; 46:311-319
33. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P: Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995; 34:713-721
34. Karson CN, Newton JEO, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA: Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993; 5:322-329
35. Gorrod JW, Fang J: On the metabolism of haloperidol. Xenobiotica 1993; 23:495-508
36. Subramanyam B, Woolf T, Castagnoli N Jr: Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 1991; 4:123-128
37. Subramanyam B, Rollema H, Woolf T, Castagnoli N Jr: Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 1990; 166:238-244
38. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 1994; 268: 380-387
39. Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, Castagnoli N Jr: 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 1994; 270:822-830
40. Eyles DW, McGrath JJ, Pond SM: Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology (Berl) 1996; 125:214-219
41. Eyles DW, Avent KM, Stedman TJ, Pond SM: Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci 1997; 60:529-534